US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.64 against a street estimate of 0.05 — a beat of 1180.0%.
Analysts rate Teva Pharma Industries Ltd ADR a buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $41.20.
| Fund | Stake |
|---|---|
| BlackRock Inc | 5.59% |
| Harel Insurance Invests & Fin Srvcs Ltd | 3.94% |
| Phoenix Financial Ltd | 3.67% |
| WCM Investment Management | 3.50% |
| MENORA MIVTACHIM HOLDINGS LIMITED | 3.40% |
| Clal Insurance Enterprises Holdings Ltd | 3.30% |
| Migdal Insurance & Financial Holdings Ltd | 3.25% |
| FMR Inc | 2.84% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-29 |
| Shareholder vote results · Q2 2026 | 2026-05-28 |
| Quarterly report · Q1 2026 | 2026-04-29 |
| Results announced · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-03-31 |
| Annual report FY2025 | 2026-02-03 |
| Results announced · Q1 2026 | 2026-01-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of Emalex Biosciences for ecopipam, first-in-class Tourette syndrome therapy Teva Pharmaceutical reported Q2 2026 revenues of $4.1 billion, down 1% year-over-year, but delivered strong growth in its strategic priority: innovative branded drugs. The company's three ke | 2026-07-29 |
| 2025 revenues $17.3B (+4% YoY), 2027 operating margin target 30% Teva Pharmaceutical reported strong 2025 results, achieving its third consecutive year of growth with revenues of $17.3 billion, up 4% year-over-year. The company's innovative drug portfolio | 2026-01-28 |
| 2025 performance and forward-looking outlook for 2026 and beyond provided Teva Pharmaceutical announced its 'Pivot to Growth' strategy at the J.P. Morgan Healthcare Conference, showcasing transformation progress and future outlook. The company expects 2025 revenue | 2026-01-12 |
| Q3 2025 results; increases 2025 outlook for Austedo and non-GAAP EPS Teva Pharmaceutical reported Q3 2025 revenues of $4.5 billion, up 3% year-over-year, marking its 11th consecutive quarter of growth. The company's innovative portfolio is the key driver, wit | 2025-11-05 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Teva Pharma Industries Ltd ADR — free to start.
Google PlayApp StoreData updated 2026-08-05.